The Food and Drug Administration (FDA) has approved a 10mg/mL solution for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 mutations….
Alunbrig Gets FDA Approval for Frontline ALK-Positive Lung Cancer Patients
FDA has approved Alunbrig or Brigatinib for first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer, as detected by FDA-approved test. This approval has been based on phase III ALTA-1L trial….
U.S. FDA Gives Nod To Bristol-Myers Combo Therapy For Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. Lung cancer patients in advanced stages of the disease have received a new first-line treatment option. The U.S. Food…
FDA Approves Tabrecta, First Targeted Therapy for NSCLC
The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung…
Lung Cancer Patients May Face Risk of Death from COVID-19
The continuous fear of COVID-19 is on the rise. With more and more people getting trapped in this pandemic, it also offers risk to those who already have health issues. The medical…
Guidance on Lung Cancer Screening During COVID-19
In this time of COVID-19 pandemic, a new expert panel has provided guidance to clinicians managing lung cancer screening programs. This statement was published in journals Radiology: Imaging Cancer, Chest and the…
Tackling Coronavirus during Lung Cancer Treatment
At the end of year 2019, a novel coronavirus was identified in Wuhan, a city in the Hubei Province of China. It spread rapidly and resulted in an increasing number of cases…
Challenges for Lung Cancer Patients amid COVID 19
Coronavirus disease 2019, or COVID 19, has rapidly evolved into a worldwide pandemic. It has become a public health emergency of international concern. Irrespective of the medical history, everyone needs to be…